Table 1.
Group | Dilution | Number of Survivors | |||||
---|---|---|---|---|---|---|---|
2 | 3 | 4 | 5 | 6 | 7 | ||
CCL35.2/ORF25 | 1:20 | 10 | 10 | 10 | 8 | 5 | 5 |
ORF25 | 1:20 | 10 | 10 | 8 | 5 | 4 | 2 |
CCL35.2/Vaccine | 1:20 | 10 | 10 | 7 | 6 | 3 | 2 |
Vaccine | 1:20 | 10 | 9 | 7 | 3 | 2 | 1 |
CCL35.2 | 1:20 | 10 | 9 | 5 | 3 | 0 | 0 |
pcDNA3.1-neo | 1:20 | 10 | 8 | 3 | 1 | 0 | 0 |
PBS | 1:20 | 10 | 9 | 3 | 2 | 0 | 0 |
Blank control | 1:20 | 10 | 10 | 10 | 10 | 10 | 10 |
Five animals were randomly selected and gathered serum on 14 dpi before virus challenge. 50 μL virus (1 × 107 TCID50mL−1) was mixed and incubated with 50 μL serum (1:20) and injected into healthy fish. In blank control, each fish was injected with 100 μL PBS without virus.